President and Handling Director of Almac’s Diagnostics ( division, Professor Paul Harkin said: ‘With Biomarkers for biopharma, we have combined a range of key solutions which are suited to growing biopharma companies ideally. For these businesses, it is of critical importance that they maximise the potential achievement of the drugs within their pipeline and the incorporation of a biomarker strategy enables them to do this.’ Almac support and guide companies, allowing biomarker strategies that will maximise their medicines and business’s potential.. Almac’s answers to support biopharma companies by adopting biomarker strategies Almac today announced the launch of Biomarkers for biopharma ( a variety of solutions made to meet the requirements of the biopharma sector specifically.‘As we gain even more clinical experience and learn more about these diseases, terminal complement inhibition with eculizumab can be a promising treatment strategy, since it targets a central mechanism of TMA.’ Soliris has been approved by healthcare authorities in the United States, European Union, Japan and other countries as the first treatment for patients with PNH, a rare, debilitating and life-threatening bloodstream disorder described by hemolysis, or the destruction of crimson blood cells. Soliris isn’t approved for the treating aHUS, MPGN, CAPS or diarrhea-linked HUS . ‘Research offered this week in Innsbruck shows that Soliris has the potential to advantage patients with a number of ultra-rare genetic diseases characterized by the current presence of TMA,’ stated Leonard Bell, M.D., Chief Executive Officer of Alexion.